References
- Iughetti L, Bruzzi P, Predieri B. Evaluation and management of hyperlipidemia in children and adolescents. Curr Opin Pediatr 2010;22:485-93
- Duivenvoorden R, Tang J, Cormode DP, et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun 2014;5:3065
- Romana B, Batger M, Prestidge CA, et al. Expanding the therapeutic potential of statins by means of nanotechnology enabled drug delivery systems. Curr Top Med Chem 2014;14:1182-93
- Thompson BJ, Ronaldson PT. Drug delivery to the ischemic brain. Adv Pharmacol 2014;71:165-202
- Drogari E, Ragia G, Mollaki V, et al. POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. Pharmacogenomics 2014;15:1963-72
- Ragia G, Kolovou V, Tavridou A, et al. Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients. Mol Diagn Ther 2014;18:323-31
- Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;385:1431-43
- Kohno T. Report of the American Heart Association (AHA) scientific sessions 2014, Chicago. Circ J 2014;79(1):34-40
- Watanabe M, Morimoto K, Houten SM, et al. Bile acid binding resin improves metabolic control through the induction of energy expenditure. PLoS One 2012;7:e38286
- Cui CJ, Li S, Li JJ. PCKS9 and its modulation. Clin Chim Acta 2015;440C:79-86
- Wierzbicki AS, Hardman TC, Viljoen A. Inhibition of pro-protein convertase subtilisin kexin-9 (PCSK9) as a treatment for hyperlipidaemia. Expert Opin Investig Drugs 2012;21:667-76
- Schulz R, Schluter K, Laufs U. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol 2015;110:4
- Galabova G, Brunner S, Winsauer G, et al. Peptide-based anti-PCSK9 vaccines – an approach for long-term LDLc management. PLoS One 2014;9:e114469
- Vergeer M, Stroes ES. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Am J Cardiol 2009;104:32E-8E
- Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99
- Wierzbicki AS, Perera D, Ewang-Emukowhate M. Dyslipidaemia: what’s around the corner? Clin Med 2014;14:s41-4
- Macchiaiolo M, Gagliardi MG, Toscano A, et al. Homozygous familial hypercholesterolemia. Lancet 2012;379:1330
- Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:998-1006
- Geary RS, Baker BF, Crooke ST. Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (Kynamro): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin Pharmacokinet 2015;54:133-46
- Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, Phase III study. Lancet 2013;381:40-6
- Noto D, Cefalù AB, Averna MR. Beyond statins: new lipid lowering strategies to reduce cardiovascular risk. Curr Atheroscler Rep 2014;16:414